StockpollyBeta
Get App
Popularity #1,575
IMMX · NASDAQ · Biotechnology

Immix Biopharma (IMMX)

Developing BCMA-targeted CAR-T therapy for relapsed or refractory AL amyloidosis.

$12.83
After hours+0.02 (+0.16%)
At close$12.81(+2.73%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
556575578111112
Research & development233241245665
222234333557
General & administrative222234333557
Operating income−5−5−6−5−7−5−5−7−8−11−11−12
000000000011
Interest income000000000011
Other non-operating income00000000000−1
Income before tax−4−5−5−4−7−5−5−7−8−11−10−12
Income tax expense000000000000
Net income from continuing operations−4−5−5−4−7−5−5−7−8−11−10−12
Net income−4−5−5−4−7−5−5−7−8−11−10−12
EPS, basic−$0.23−$0.26−$0.22−$0.15−$0.24−$0.17−$0.15−$0.22−$0.24−$0.28−$0.18−$0.18
EPS, diluted−$0.23−$0.26−$0.22−$0.15−$0.24−$0.17−$0.15−$0.22−$0.24−$0.28−$0.18−$0.18
Weighted average shares, basic192023292928303032385564
Weighted average shares, diluted192023292928303032385564
EBITDA−5−5−5−4−7−5−4−7−7−11−11−12
Depreciation & amortization000000000000
EBIT−5−5−5−4−7−5−5−7−8−11−11−12